Blast Crisis - 24 Studies Found Completed : Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia : Chronic Myeloid Leukemia Leukemia, Lymphoblastic, Acute, Philadelphia-positive : 2005-01-12 : Drug: Dasatinib Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, sw Completed : BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia : Leukemia, Myeloid, Chronic-phase Leukemia, Lymphoblastic, Acute, Philadelphia-positive : 2005-02-14 : Drug: Dasatinib Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response. Completed : Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia : Leukemia : 2008-12-31 : Drug: dasatinib 50 mg orally 2 Recruiting : An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) : Leukemia : 2011-12-21 : Drug: Dasatinib Starting Dose: <<< Previous
